Key clinical point: Performing left ventricular ejection fraction (LVEF) measurement before doxorubicin chemotherapy may not be helpful.
Major finding: Among diffuse large B-cell lymphoma (DLBCL) patients who had LVEF measured, the incidence of heart failure post treatment did not differ between patients who received doxorubicin and those who did not (P = 1.0).
Study details: A retrospective analysis of 291 patients diagnosed with DLBCL between 2001 and 2013.
Disclosures: The researchers reported having no competing interests.
Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85.
This Week's Must Reads
Must Reads in Lymphoma & Plasma Cell Disorders
Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Outcomes Post-AlloSCT in DHL/DEL Lymphomas, Biol Blood Marrow Transplant; ePub 2017 Nov 28; Herrera, et al
Anthracycline-Related CV Dysfunction Evaluated, Cancer; ePub 2017 Nov 7; Armenian, Mertens, et al
Adcetris Approved for Primary Cutaneous ALCL, FDA news release; 2017 Nov 9